VDRM (ViaDerma) EBIT: $3.76 Mil (TTM As of Jun. 2012)


What is ViaDerma EBIT?

ViaDerma VDRM -25.00% EBIT is $3.76 Mil as of Jun. 2012.

ViaDerma's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2012 was $1.52 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2012 was $3.76 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ViaDerma's annualized ROC % for the quarter that ended in Jun. 2012 was 10.58%. ViaDerma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2012 was 14.95%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ViaDerma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2012 was 1,014.86%.

ViaDerma  (OTCPK:VDRM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ViaDerma's annualized ROC % for the quarter that ended in Jun. 2012 is calculated as:

ROC % (Q: Jun. 2012 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2012 ) + Invested Capital (Q: Jun. 2012 ))/ count )
=6.084 * ( 1 - 28.75% )/( (40.786 + 41.193)/ 2 )
=4.33485/40.9895
=10.58 %

where

Invested Capital(Q: Mar. 2012 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=44.93 - 2.774 - ( 1.37 - max(0, 7.719 - 17.218+1.37))
=40.786

Invested Capital(Q: Jun. 2012 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=45.832 - 3.452 - ( 1.187 - max(0, 7.872 - 16.925+1.187))
=41.193

Note: The Operating Income data used here is four times the quarterly (Jun. 2012) data.

2. Joel Greenblatt's definition of Return on Capital:

ViaDerma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2012 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2012 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2012  Q: Jun. 2012
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=6.092/( ( (27.712 + max(12.579, 0)) + (28.908 + max(12.286, 0)) )/ 2 )
=6.092/( ( 40.291 + 41.194 )/ 2 )
=6.092/40.7425
=14.95 %

where Working Capital is:

Working Capital(Q: Mar. 2012 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(13.304 + 0.334 + 2.21) - (2.774 + 0 + 0.495)
=12.579

Working Capital(Q: Jun. 2012 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(14.132 + 0.612 + 0.994) - (3.452 + 0 + 0)
=12.286

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2012) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ViaDerma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2012 )
=3.755/0.370
=1,014.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViaDerma EBIT Related Terms

ViaDerma EBIT Historical Data

* Premium members only.

The historical data trend for ViaDerma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViaDerma EBIT Chart

ViaDerma Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11
EBIT
-0.14 9.01 6.40 7.77 4.05

ViaDerma Quarterly Data
Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.56 0.70 0.81 0.73 1.52

VDRM vs AOLS, RDGL, PCYN: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ViaDerma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ViaDerma EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ViaDerma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ViaDerma's EV-to-EBIT falls into.


ViaDerma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $3.76 Mil mean?
ViaDerma (VDRM) has a EBIT of $3.76 Mil as of Jun. 2012. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ViaDerma.
Is ViaDerma's EBIT too high?
ViaDerma's current EBIT is $3.76 Mil.
How does ViaDerma's EBIT compare to AOLS and RDGL?
ViaDerma's EBIT of $3.76 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ViaDerma. ViaDerma's current EBIT is $3.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViaDerma stock overvalued right now?
ViaDerma (VDRM) has a current EBIT of $3.76 Mil. The current EBIT is $3.76 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For ViaDerma (VDRM), the current EBIT is $3.76 Mil as of Jun. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ViaDerma Business Description

Address 4640 Admiralty Way, Suite 500, Marina Del Rey, CA, USA, 90292
ViaDerma Inc is a specialty pharmaceutical company focused to bring new products to market through research and development. It is engaged in the business of manufacturing and sales of pharmaceuticals, and specifically topical antibiotics and pain management in the United States of America. Its sells under the brand name Vitastem. The Company also has products in development in the fields; anti-aging skin care, pain management, hair-loss, and toenail fungus.